The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Optimer Pharmaceuticals beat slightly on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.
Margins grew across the board.
Optimer Pharmaceuticals reported revenue of $17.9 million. The 11 analysts polled by S&P Capital IQ expected revenue of $17.6 million on the same basis. GAAP reported sales were 62% higher than the prior-year quarter's $11.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.56. The eight earnings estimates compiled by S&P Capital IQ predicted -$0.63 per share. GAAP EPS were -$0.56 for Q3 against -$0.57 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 25.3%, 2,500 basis points better than the prior-year quarter. Operating margin was -147.0%, 9,650 basis points better than the prior-year quarter. Net margin was -149.8%, 8,930 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $19.0 million. On the bottom line, the average EPS estimate is -$0.44.
Next year's average estimate for revenue is $100.7 million. The average EPS estimate is -$1.41.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 108 members out of 142 rating the stock outperform, and 34 members rating it underperform. Among 46 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Optimer Pharmaceuticals a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is outperform, with an average price target of $19.13.
- Add Optimer Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Coming Soon: Optimer Pharmaceuticals Earnings
Why Optimer Pharmaceuticals Shares Sank
Dificid delivers a deficit with regard to Wall Street's expectations.
Optimer Pharmaceuticals Misses on the Top and Bottom Lines
Just the facts, Fool.